ERBB is frequently elevated in Ph+ ALL, and ERBB/HER2/NEU inhibitor lapatinib was synergistic with imatinib and nilotinib (but not dasatinib) on Ph+ ALL cell lines with high ERBB expression (63). This evidence concerns the gene ERBB2 and acute lymphoblastic leukemia.